Heartbeat’s Post

Sharing a nice summary of conversations I had after the 2023 #clinicaltrials in #oncology #europe (CTOEU2023) meeting in Munich! On the topic of #patientcentricity and #patientengagement in clinical trials. We need to work collectively through the challenges and seize the opportunities to transform the conduct of clinical trials to be more #inclusive of more patients and prioritise their needs for participation #patientsfirst

🔍 Q&A Insight: Navigating Oncology Trials' Complex Terrain 🔬 🎙️ Pauline Frank, a beacon in the field of clinical research, recently shared her reflections from the 2023 CTO Europe conference. Her session, rooted in her experience as the former director of patient engagement at Novartis, shed light on the intricate complexities of conducting oncology trials. 🚀 Despite advancements, these trials face significant hurdles, notably in patient awareness and diversity. Pauline's dialogue with Pharmaceutical Technology delves into these challenges and explores the potential of digital technologies in revolutionizing these complex trials. 🔑 Key Challenges for Patients: Lack of public awareness about clinical trials Misconceptions and communication barriers Geographic and language limitations affecting patient participation 🤔 Improving Patient Engagement: Enhancing health literacy Developing effective communication materials Considering the patient's perspective in trial design 🌍 The Digital Dilemma: Need for a tailored approach based on patient demographics Importance of human interaction alongside digital tools 📣 Social Media & Health Literacy: Leveraging social media for awareness and recruitment Tailoring messages to specific patient groups 🌈 Fostering Diversity in Trials: Engaging physicians from diverse backgrounds Providing materials in native languages and understanding cultural nuances 👏 A big thanks to Pauline Frank for her invaluable contributions and insights! #OncologyTrials #PatientEngagement #ClinicalResearch #DigitalHealth #DiversityInHealthcare #CTOEurope2023 #Novartis

🚨 Join Us at AVBCC Conference, October 16-19! 🚨 Excited to announce that we will be participating in a panel discussion at the AVBCC Conference, focusing on the future of radiation oncology and what it takes to ensure access, improve quality, and stabilize payments under a value driven model. 💡 Our expert panel brings together leaders from industry, payers, health policy, and physicians to tackle some of the biggest challenges and trends in the field. We'll cover key topics such as: 1️⃣ Standardization vs. Personalization in clinical pathways—finding the balance with AI and precision medicine. 2️⃣ Multidisciplinary Integration—how clinical pathways can ensure seamless coordination across treatment modalities. 3️⃣ Value-Based Care—designing pathways that align with value-based models, reduce costs, and improve outcomes. 4️⃣ Access to Advanced Technologies—ensuring equitable access to cutting-edge treatments, especially for underserved populations. 5️⃣ Data-Driven Pathways—using real-world evidence and analytics to continuously improve patient outcomes. 6️⃣ Navigating Regulatory and Legal Challenges—addressing prior authorization, Medicare/Medicaid reforms, and compliance. 7️⃣ Telemedicine and Digital Health—incorporating remote care and digital tools into clinical pathways. 8️⃣ AI and Machine Learning—how AI-driven tools will shape the future of clinical pathway development. 9️⃣ Global Perspectives—learning from international approaches to radiation therapy access and pathway development. 🔟 Clinical Trials Integration—accelerating innovation through adaptive trials and real-time data. This is a can't-miss discussion for anyone invested in the future of radiation oncology! Be sure to join us for insights that will drive the path forward. 🌟 Lalan Wilfong, M.D. CancerX Moonshot OncoDaily OncoHealth Carrum Health Cardinal Health McKesson The US Oncology Network Florida Blue Premera Blue Cross Takeda Pfizer Seema Verma American Hospital Association American Medical Association Burt Zweigenhaft National Rural Health Association Douglas Flora, MD, LSSBB, FACCC #AVBCC #RadiationOncology #ClinicalPathways #ValueBasedCare #HealthPolicy #OncologyInnovation #HealthcareLeadership #AIinHealthcare

Patient-centricity in clinical research #Patient-centricity is a keyword or buzzword many of us hear about in conferences. In the Asia-Pacific region which patient-centric solutions have been present in patient facing solutions for clinical care, we're at the beginnings of truly embedding patient-centricity when it comes to clinical research. Involving patients in the early stages of clinical research ensures that research priorities align with patient needs, ultimately leading to the development of more relevant and impactful interventions. Post-marketing, patient engagement facilitates the collection of real-world evidence, providing insights into treatment effectiveness and safety in diverse patient populations. Within clinical development, patient input aids in the design of more patient-friendly trials, leading to improved recruitment and retention. Market authorization and reimbursement processes benefit from patient involvement as well, ensuring that approved treatments address unmet patient needs and are accessible to those who can benefit from them. Embracing a patient-centric approach at each stage not only enhances the relevance and effectiveness of healthcare interventions but also fosters a sense of inclusivity and empowerment among patients. But is this all there is to patient-centricity in clinical research and can we do more? At @Oncoshot, we're very excited about new models of patient-centricity that can be enabled with data. If you're a healthcare system and would like to explore our futuristic work with #preconsent solutions for clinical trials and research, do reach out to us. #patient-centricity #clinicalresearch #cancer #clinicaltrials #patient #preconsent

Many of our clients realize the value of embedding the patient voice early in the drug development process, starting in clinical trials. Sprout's Kelsie Brewer is the newest member of our Clinical Outcomes Assessment (COA) team, specialists who advise biotech and HEOR clients on building clinical endpoints that resonate with patients and are on track for regulatory success. Kelsie brings expertise in patient-centered qualitative research across rare disease, oncology, neurology, and rheumatology. Read more about Kelsie and the work she is most excited about. #PatientVoice #ClinicalOutcomes #HEOR

🔬 Did you know that behind every medical breakthrough are #ClinicalTrials and the brave people who participate in them? With their commitment, each volunteer not only gets closer to a possible new solution for their own #health, but also helps #Science save or improve millions of lives in the future. 💊 These trials are the last critical step in the long process of new drug research and development. From the selection of new molecules to the post-marketing monitoring of a drug, they represent the cornerstone that ensures that treatments are not only effective, but also safe for everyone. 🌍 That's why today, on #InternationalClinicalTrialDay, we want to highlight their great contribution to #MedicalResearch and to the transformation of thousands of lives. From Bristol Myers Squibb we are proud to be part of this milestone thanks to the development of multiple clinical trials involving an increasing number of patients in #Oncology, #Hematology, #Cardiology, #Immunosciences and other areas. 🧪 🤝🏼 Our sole objective is to continue transforming patients' lives through our innovative #Science, and to this end we are grateful for the fundamental role that institutions, researchers, healthcare professionals and, especially, patients play in clinical trials. Thank you all! ❤️ Discover the importance of clinical trials and the positive impact patients have on the advancement of medicine with this video. Press play! ▶️ 🔗 More information at https://lnkd.in/dB-efXjm #InternationalClinicalTrialDay #MedicalResearch #ClinicalTrials #GlobalHealth #ValentPatients #BMSIberia #BMSPortugal #BMSCommunity #BMSTransformingLives #WorkingTogetherforPatients #BMSTransformingPatientsLives 

🔬 Oncology is one of the biggest challenges for modern medicine. The variety, complexity and severity of the disease keep doctors and researchers constantly looking for ways to improve treatment in different ways. 📑 A review by Cureus Journal of Medical Science looks at how digital health can help in this multifaceted solution for oncology patients. 💡 It discusses potential for early detection, personalized treatment, enhanced care coordination, patient empowerment, accelerated research, and cost efficiency. It also acknowledges the challenges, including ethical considerations regarding privacy, equitable access, and responsible data usage. "The landscape of digital health in oncology is marked by incredible promise and transformative potential," concludes the article. Through our collaborative efforts and innovative products, we aim to make significant strides in these areas, My Medic Eye is committed to tackling the challenges of accessibility, equality of care, patient engagement and families' involvement in the situation and treatment of their loved ones. Our free app empowers users by facilitating efficient management of medical records and active participation in their treatment journeys. Building upon this success, our upcoming tool will streamline information exchange among caregiver services, clinics, and medical centers. This innovation not only enhances patient care but also supports medical teams and ensures smooth administrative processes. Are you ready to join us on this transformative journey? Contact us today to learn more 🚀 Link to the full review: https://lnkd.in/dXSsnfak #DigitalHealth #HealthcareInnovation #PatientCare #MedicalTechnology

🔬 Elevating the value of CRO Partnerships: The Power of Data 🔬 In the dynamic realm of oncology clinical research, the partnership between Contract Research Organizations (CROs) and sponsors holds immense significance. At Leal Health, we're pioneering a transformative approach that harnesses the impact of data to redefine how studies are conducted and outcomes are achieved. Consider the following key points: Specialized Approach: 🎯 In oncology research, it's vital for CROs to exhibit a highly specialized approach, understanding the unique challenges and gaining the trust of both the sponsors and patient populations. Unprecedented Access: 🌟 With access to over 175,000 cancer patients, we empower CROs & sponsors by facilitating the education, empowerment, and enrollment of highly qualified patients into their studies. Comprehensive Insights: 📊 Our platform doesn't just stop at patient recruitment. We provide a comprehensive breakdown, including demographics, disease characteristics, patient preferences, and enrollment & eligibility barriers. Strategic Impact: 🚀 Imagine the impact of being able to convey detailed study status, identify challenges, and implement effective mitigation strategies to sponsors. At Leal Health, we're revolutionizing the value proposition of CROs by leveraging: Interdisciplinary Team: 🧠 Our in-house clinical team comprises PhDs, cancer researchers, nurses, social workers, and oncologists, ensuring a holistic approach to research and patient support. Cutting-edge Technology: 💻 Proprietary AI technology and algorithms drive our insights, enabling us to deliver precise and actionable data-driven solutions, identify, & match highly qualified patients in minutes. By seamlessly integrating expertise with technology, we're redefining the possibilities in oncology clinical research. Reach out today to discover how Leal Health can empower your studies and drive meaningful progress. Contact jamesr@leal.health to learn more! #OncologyResearch #ClinicalTrials #DataDrivenInsights #CRO #SponsorPartnership #InnovationInHealthcare

Aptar Digital Health's Strategic Acquisition of Healint: Forging New Frontiers in Patient-Centric Care Let's look into this recent development in more detail: - 🚀 **Aptar Digital Health acquires Healint**, a trailblazer in digital health for neurological and immunological conditions, enhancing its digital health portfolio. - 🧠 **Expansion into neurology**: The acquisition broadens Aptar’s capabilities in patient community management, AI-driven data analysis, and digital diagnostics, reinforcing its commitment to neurology and immunology. - 🌍 **Global reach for clinical studies**: Healint's expertise in conducting global virtual clinical studies and its robust platforms like Migraine Buddy and Clarrio app, will now complement Aptar’s offerings to pharmaceutical clients, enabling faster and broader clinical trials. - 📈 **Empowering patient care through technology**: With over three million users of Migraine Buddy, Healint brings proven patient engagement and real-world evidence generation to Aptar, aiming to enhance treatment outcomes and speed up clinical trial processes. - 🤖 **Innovation through AI and data analytics**: The merger integrates Healint’s AI and sensor data analytics with Aptar’s digital health solutions, promising advancements in precision medicine and patient care in the digital age. Let's keep the discussion going! What are your views on: - 💡 How can digital health companies further innovate to meet the unique needs of patients with neurological conditions? - 🌐 What impact will the merger have on the global scalability of digital health solutions, particularly in underserved regions? - 🔍 In what ways can AI-powered precision medicine transform the landscape of patient care and clinical trials? Please share your thoughts and like / share this post to see more like it! Reach out to #LucidQuest at info@lqventures.com to find out more about what we do and how we can support your brand to thrive! #DigitalHealth #AptarDigitalHealth #Healint #MigraineBuddy #AIHealthcare #ClinicalTrials #Neurology #Immunology #PatientCare #PrecisionMedicine #lucidquest

Campaign Spotlight: Grey Matters – A Brain Tumor Awareness Campaign In June, we launched the "Grey Matters" campaign, focused on raising awareness about brain tumors. This initiative was deeply meaningful, aiming to educate and engage people on a critical health issue that often goes unnoticed. After the campaign, we conducted a post-marketing assessment to evaluate its reach and impact. I was thrilled to see that our multidimensional approach, including digital media, patient stories, and collaborations with healthcare professionals, resulted in an exceptionally strong reach. Our estimates revealed that our message resonated with a broad audience, demonstrating the power of a well-rounded strategy. Why Post-Marketing Assessment Matters: Campaigns like "Grey Matters" are only as effective as their ability to reach and influence the target audience. Post-marketing assessment is crucial as it allows us to: 1. Measure Impact: Understand the extent of our campaign’s reach and effectiveness. 2. Gather Insights: Learn what worked and what didn’t, enabling us to refine our strategies for future campaigns. 3. Prove Value: Demonstrate the campaign’s value to stakeholders through tangible results. 4. Continuous Improvement: Drive future initiatives with data-driven decisions, ensuring we keep making healthcare better. Through these assessments, we ensure that our efforts are not just a one-time event but a continuous process of learning and improving, ultimately making a bigger impact on patient lives. #HealthcareMarketing #BrainTumorAwareness #PostMarketing #PatientEngagement #HealthCampaigns #ContinuousImprovement #HealthcareInnovation ---------------------‐-------------------------------------------- Disclaimer: The estimates shared here are based on my personal analysis. They do not reflect official statistics from Stryker, and I am not speaking on behalf of the organization. The insights shared are my own subjective observations and interpretations.